Emergent BioSolutions (NYSE:EBS) Trading 3.2% Higher – What’s Next?

Emergent BioSolutions Inc. (NYSE:EBS) shares were up 3.2% during trading on Monday . The company traded as high as $9.74 and last traded at $9.65. Approximately 525,477 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 3,530,859 shares. The stock had previously closed at $9.35.

Analyst Ratings Changes

Several research firms have recently weighed in on EBS. Rodman & Renshaw reiterated a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark reiterated a “buy” rating and issued a $8.00 price target on shares of Emergent BioSolutions in a report on Friday, August 16th.

Emergent BioSolutions Stock Down 5.3 %

The company has a current ratio of 1.06, a quick ratio of 0.54 and a debt-to-equity ratio of 1.16. The firm’s 50 day moving average price is $8.43 and its two-hundred day moving average price is $7.14. The company has a market capitalization of $458.26 million, a price-to-earnings ratio of -0.84 and a beta of 1.59.

Emergent BioSolutions (NYSE:EBS) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The business had revenue of $254.70 million for the quarter, compared to the consensus estimate of $199.47 million. During the same quarter in the prior year, the firm posted ($1.06) earnings per share. Sell-side analysts anticipate that Emergent BioSolutions Inc. will post -1.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Emergent BioSolutions

A number of institutional investors have recently modified their holdings of the business. Los Angeles Capital Management LLC boosted its stake in shares of Emergent BioSolutions by 20.1% in the first quarter. Los Angeles Capital Management LLC now owns 193,991 shares of the biopharmaceutical company’s stock valued at $491,000 after buying an additional 32,460 shares during the period. SeaCrest Wealth Management LLC acquired a new stake in shares of Emergent BioSolutions during the 1st quarter worth $243,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Emergent BioSolutions during the 1st quarter worth $57,000. BNP Paribas Financial Markets increased its position in shares of Emergent BioSolutions by 155.3% in the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock worth $414,000 after purchasing an additional 99,520 shares during the period. Finally, Fidelis Capital Partners LLC acquired a new position in Emergent BioSolutions in the first quarter valued at about $67,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.